Researcher
Jens Tijtgat
- Keywords:Medicine
- Disciplines:Natural sciences, Social sciences
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Medical Oncology (Department)
Member
From1 Aug 2020 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From6 Jul 2020 → Today - Faculty of Economic and Social Sciences and Solvay Business School (Faculty)
Member
From2 Jul 2022 → 18 Nov 2022 - Clinical sciences (Department)
Member
From1 Aug 2020 → 14 Jan 2024 - Clinical sciences (Department)
Member
From1 Aug 2020 → 20 Oct 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From6 Jul 2020 → 17 Jan 2024 - Faculty of Medicine and Pharmacy (Faculty)
Member
From28 Jul 2017 → 25 Jun 2020
Publications
1 - 10 of 13
- Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma(2024)
Authors: Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses G Forsyth, Ivan Van Riet, et al.
- 1136P Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases(2023)
Authors: Iris Dirven, An-Sofie Vander Mijnsbrugge, Jens Tijtgat, Manon Vounckx, Bart Neyns
Pages: 681-681 - Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia(2023)
Authors: Iris Dirven, An-Sofie Vander Mijnsbrugge, Sacha Mignon, Jens Tijtgat, Nicolas Kint, Bart Neyns
Pages: 338-344 - Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series(2023)
Authors: Jens Tijtgat, Evan Maarten Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, A Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, et al.
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Authors: Julia Katharina Schwarze, Jens Tijtgat, G Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses G Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pages: 1-13 - A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Authors: G Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pages: 183-191 - Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Authors: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, G Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Authors: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, K Breckpot, Joeri L Aerts, Bart Neyns, Sandra Tuyaerts
- Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Authors: Jens Tijtgat, Julia Katharina Schwarze, G Awada, Bart Neyns, Sandrine Aspeslagh
Pages: 272-276 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Authors: G Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns